<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01804218</url>
  </required_header>
  <id_info>
    <org_study_id>U01-BCM-01</org_study_id>
    <nct_id>NCT01804218</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Invion, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Invion, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test the hypothesis that 18—22 week treatment with the
      inverse agonist nadolol will improve airway hyperresponsiveness in patients with mild asthma,
      compared to placebo.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Actual">May 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in methacholine provocative concentration causing a 20% fall (PC20) based on forced expiratory volume in 1 second (FEV1) between baseline visit and final dose dispensing visit.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Mild Persistent Asthma, Uncomplicated</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Active, nadolol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nadolol</intervention_name>
    <arm_group_label>Active, nadolol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Individuals who meet all of the following criteria are eligible for enrollment as study
        participants:

        1. Males and females with physician-diagnosed asthma between the ages of 18- 60.

        2. Pre-bronchodilator FEV1 80% or greater than the predicted value

        3. Baseline PC20 (based on FEV1) ≤ 4 mg/ml on methacholine challenge test.

        4. Asthma Control Questionnaire Score (ACQ) &lt;1.25

        5. Baseline blood pressure ≥ 110/65mm Hg

        6. Baseline pulse rate ≥ 60 beats/min.

        7. Never-smoker or former-smoker &lt; 10 pack.year and has not smoked within 1 year.

        8. Able to complete diary cards and comply with study procedures.

        9. Females of childbearing age may participate only if they have a negative pregnancy test,
        are non-lactating, and agree to practice an adequate birth control method (abstinence,
        combination barrier and spermicide, or hormonal) for the duration of the study.

        Exclusion Criteria:

        Subjects who meet ANY of the following criteria are not eligible for enrollment:

          1. Inability or unwillingness of the participant to give written informed consent

          2. History of upper/lower respiratory tract infection or asthma exacerbation requiring
             systemic steroids within 6 weeks of Visit 1

          3. Use of rescue medication (e.g., albuterol) more than twice per week during the week
             preceding Visit 1 excluding the use of such medication as preventative prior to
             exercise.

          4. History of hospitalization for asthma in the preceding year

          5. History of intubation for asthma

          6. Currently diagnosed with chronic obstructive pulmonary disease (COPD)

          7. Currently taking any beta-blocker medication

          8. History of adverse reaction or allergy to any beta-blocker medication

          9. History of neurological, hepatic, renal, or other medical conditions that may
             interfere with the interpretation of data or the patient's participation in the study
             or may increase safety concerns

         10. Current diabetes or hyperthyroidism

         11. History of cardiovascular diseases including uncontrolled hypertension (BP &gt;160/100),
             ischemic heart disease, congestive heart failure, valvular heart disease or
             cardiomyopathy

         12. Known allergy or sensitivity to atropine or ipratropium bromide

         13. Abnormal entry laboratory values at baseline except for the following tests, where
             values outside the normal limits will be acceptable as follows: Hct ≥ 30%, platelet
             count &gt; 100,000, ALT and AST &lt; 1.5 x upper normal limit

         14. Known bleeding disorders, platelet count &lt;100,000, PT or PTT &gt; 1.5 x normal control
             (if participating in bronchoscopy sub-study)

         15. Known allergy to lidocaine (if participating in bronchoscopy sub-study)

         16. Documented or self-reported current history of alcoholism or drug abuse

         17. Participation in another research trial within 30 days of starting this trial

         18. Unwillingness or inability to comply with study procedures

         19. Inability to swallow the study medication capsule

         20. Use of any exclusion medication within the time period specified

         21. Pregnant or nursing

         22. Receiving allergen immunotherapy (desensitization injections)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicola A. Hanania, MD, MS</last_name>
    <role>Study Chair</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2013</study_first_submitted>
  <study_first_submitted_qc>March 1, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2013</study_first_posted>
  <last_update_submitted>August 5, 2016</last_update_submitted>
  <last_update_submitted_qc>August 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nadolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

